Neumora Therapeutics Inc (NASDAQ: NMRA) is -23.64% lower on its value in year-to-date trading and has touched a low of $8.33 and a high of $21.00 in the current 52-week trading range. The question becomes, what are the chances the stock will make a comeback and enjoy potential growth. Why not look at analysts view on what the future holds for the stock. The NMRA stock was last observed hovering at around $12.71 in the last trading session, with the day’s gains setting it 0.31%.
Currently trading at $13.02, the stock is -4.15% and 0.34% above its SMA20 and SMA50 respectively. However, with a daily trading volume of 1.08 million and changing 2.44% at the moment leaves the stock 3.12% off its SMA200. NMRA registered 12.24% gain for a year compared to 6-month gain of 33.27%. The firm has a 50-day simple moving average (SMA 50) of $12.9471 and a 200-day simple moving average (SMA200) of $12.637975.
The stock witnessed a -9.01% loss in the last 1 month and extending the period to 3 months gives it a 15.63%, and is 13.71% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 8.06% over the week and 7.66% over the month.
Neumora Therapeutics Inc (NMRA) has around 124 employees, a market worth around $2.08B and $0.00M in sales. Distance from 52-week low is 56.30% and -38.00% from its 52-week high. The company has generated returns on investments over the last 12 months (-71.91%).
The EPS is expected to grow by 59.29% this year
140.0 institutions hold shares in Neumora Therapeutics Inc (NMRA), with institutional investors hold 86.01% of the company’s shares. The shares outstanding are 158.83M, and float is at 54.91M with Short Float at 16.41%. Institutions hold 61.93% of the Float.
Neumora Therapeutics Inc (NMRA) Insider Activity
The most recent transaction is an insider sale by Fust Matthew K, the company’s Director. SEC filings show that Fust Matthew K sold 14,049 shares of the company’s common stock on Oct 18 ’24 at a price of $17.03 per share for a total of $0.24 million. Following the sale, the insider now owns 20100.0 shares.
Neumora Therapeutics Inc disclosed in a document filed with the SEC on Oct 17 ’24 that Fust Matthew K (Director) sold a total of 7,739 shares of the company’s common stock. The trade occurred on Oct 17 ’24 and was made at $17.01 per share for $0.13 million. Following the transaction, the insider now directly holds 20100.0 shares of the NMRA stock.
Still, SEC filings show that on Oct 18 ’24, Fust Matthew K (Director) Proposed Sale 14,049 shares at an average price of $17.03 for $0.24 million. The insider now directly holds shares of Neumora Therapeutics Inc (NMRA).
